Williams Cancer Institute

Anti-CD47 A New Upcoming Immunotherapy Agent

CD47 is a protein that is present on the surface of many types of cancer cells. It acts as a “don’t eat me” signal, sending a signal to immune cells such as macrophages not to engulf and destroy the cancer cell.

Research into CD47 as a target for cancer immunotherapy has shown promising results. One approach involves using antibodies to block the CD47 protein, allowing immune cells to recognize and attack the cancer cells. This approach is sometimes called the “don’t eat me” signal-blocking strategy.

Preclinical studies have shown that blocking CD47 can stimulate an immune response against cancer cells, resulting in the destruction of tumor cells. In animal studies, CD47 blockade has been shown to shrink tumors and even lead to complete regression of some types of cancer.

Intratumoral injection of anti-CD47 antibodies is a novel approach to cancer immunotherapy that aims to enhance the immune response against cancer cells by blocking the “don’t eat me” signal that is sent by CD47 protein.

In this approach, anti-CD47 antibodies are injected directly into tumors, rather than being delivered systemically. The idea behind this approach is that by injecting the antibodies directly into the tumor, higher concentrations of the antibody can be delivered to the cancer cells, while minimizing the risk of systemic toxicity.

Preclinical studies have shown that intratumoral injection of anti-CD47 antibodies can enhance the activity of immune cells, leading to the destruction of cancer cells within the tumor. This approach has been shown to be effective in various types of cancer, including breast cancer, ovarian cancer, and bladder cancer.

Early-phase clinical trials of intratumoral anti-CD47 therapy are ongoing, and initial results have been promising. For example, a phase 1 clinical trial of intratumoral anti-CD47 therapy in patients with advanced solid tumors found that the therapy was well-tolerated and resulted in some tumor shrinkage.

Overall, intratumoral anti-CD47 therapy represents a promising approach to cancer immunotherapy, and may offer a new way to enhance the immune response against cancer cells. However, more research is needed to fully understand the safety and effectiveness of this approach, and to determine which types of cancer and patient populations may benefit most from this therapy.

Reference: Bazarbachi, A. (14 de May de 2020). Anti-CD47 a new upcoming immunotherapy agent. Blood, 135(20), 1730-1731. doi:10.1182/blood.2020005755

Related Posts

Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
Blog 06 de mayo de 2024
1 2 3 111